Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03968393 · ClinicalTrials.gov registry record · Phase 4
Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress
A Phase 4 study of Stroke and Atrial Fibrillation, sponsored by Population Health Research Institute.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 2,270
- Enrollment target
- 20
- Study locations
NCT03968393 is a Phase 4 study of Stroke and Atrial Fibrillation that is actively recruiting participants, run by Population Health Research Institute. The registered enrollment target is 2,270 participants, below the 12,011-participant average among 454 other Stroke trials with a reported enrollment target (81% lower). The trial reports 20 study locations across 10 states.
The verdict
NCT03968393, a Phase 4 study of Stroke and Atrial Fibrillation, is actively recruiting participants, sponsored by Population Health Research Institute.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 2,270 participants
- Enrollment target
- 20
- Study locations
Study Summary
Multinational, investigator-initiated study of oral anticoagulation versus no anticoagulation for the prevention of stroke and other adverse cardiovascular events in patients with transient atrial fibrillation occurring transiently with stress and additional stroke risk factors.
Conditions Studied
Interventions
- DRUG Non-vitamin K oral anticoagulant (NOAC)
Study Locations (20)
New South Wales
- Bankstown Hospital - Bankstown
- Royal Prince Alfred Hospital - Camperdown
- Concord Repatriation General Hospital - Concord
- Liverpool Hospital - Liverpool
- John Hunter Hospital - Newcastle
- Westmead Hospital - Westmead
Other
- Hospital Municipal Chivilcoy - Chivilcoy
- Sanatorio Cisma - San Miguel de Tucumán
- Hospital Privado de Rosario - Santa Fe
Queensland
- Sunshine Coast Hospital and Health Service - Birtinya
- Royal Brisbane and Women's Hospital - Herston
- Redcliffe Hospital - Redcliffe
Santa Fe Province
- Instituto de Investigaciones Clinicas Rosario - Rosario
- Instituto Cardiovascular de Rosario - Rosario
California
- Cedars-Sinai Medical Center - Los Angeles
Texas
- Mcgovern Medical School at University of Texas - Houston
Buenos Aires
- Clinica Coronel Suarez - Coronel Suárez
Tucumán Province
- Centro Integral de Arritmias de Tucuman (CIAT) - San Miguel de Tucumán
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,270 participants |
| Start Date | 2019-06-14 |
| Est. Completion | 2028-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03968393
The ClinicalTrials.gov registry entry for NCT03968393 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 2,270 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 12,011-participant average among 454 other Stroke trials with a reported enrollment target (81% lower). The listed sponsor is Population Health Research Institute, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Stroke appearing as the primary indexed condition, and to 1 intervention - of which Non-vitamin K oral anticoagulant (NOAC) is the first listed.
NCT03968393 reports 20 study locations spanning 10 distinct geographic areas - top geographies include New South Wales, Other, Queensland.
Frequently Asked Questions
What is clinical trial NCT03968393 about?
NCT03968393 is a clinical study titled "Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress". Multinational, investigator-initiated study of oral anticoagulation versus no anticoagulation for the prevention of stroke and other adverse cardiovascular events in patients with transient atrial fibrillation occurring transiently with stress and additional stroke risk factors.
What is the current status of trial NCT03968393?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 2,270 participants. The study started on 2019-06-14. Estimated completion is 2028-12.
What conditions does trial NCT03968393 study?
This clinical trial studies the following conditions: Stroke, Atrial Fibrillation.
What interventions are being tested in trial NCT03968393?
The interventions under investigation include: Non-vitamin K oral anticoagulant (NOAC) (DRUG).
Who is sponsoring clinical trial NCT03968393?
This trial is sponsored by Population Health Research Institute, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03968393 being conducted?
This trial has 20 study locations across California, Texas, Buenos Aires, Santa Fe Province, Tucumán Province. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stroke
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
International Care Bundle Evaluation in Cerebral Hemorrhage Research
RECRUITING · Phase 4
-
Xeomin® and Gait Related Mobility After Stroke
RECRUITING · Phase 4
-
EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction
ACTIVE NOT RECRUITING · Phase 4
-
SEdation Versus General Anesthesia for Endovascular Therapy in Acute Ischemic Stroke
COMPLETED · Phase 4
-
Gait Training For Acute Stroke: Functional Neuromuscular Stimulation (FNS) and Weight Supported Treadmill Training
COMPLETED · Phase 4
-
Improving Cardiovascular Risk Prediction Using Hand Held Carotid Ultrasonography Study
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.